Modeling of Effective Antimicrobials to Reduce Staphylococcus aureus Virulence Gene Expression Using a Two-Compartment Hollow Fiber Infection Model

Toxins (Basel). 2020 Jan 22;12(2):69. doi: 10.3390/toxins12020069.

Abstract

Toxins produced by community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) contribute to virulence. We developed a statistical approach to determine an optimum sequence of antimicrobials to treat CA-MRSA infections based on an antimicrobial's ability to reduce virulence. In an in vitro pharmacodynamic hollow fiber model, expression of six virulence genes (lukSF-PV, sek, seq, ssl8, ear, and lpl10) in CA-MRSA USA300 was measured by RT-PCR at six time points with or without human-simulated, pharmacokinetic dosing of five antimicrobials (clindamycin, minocycline, vancomycin, linezolid, and trimethoprim/sulfamethoxazole (SXT)). Statistical modeling identified the antimicrobial causing the greatest decrease in virulence gene expression at each time-point. The optimum sequence was SXT at T0 and T4, linezolid at T8, and clindamycin at T24-T72 when lukSF-PV was weighted as the most important gene or when all six genes were weighted equally. This changed to SXT at T0-T24, linezolid at T48, and clindamycin at T72 when lukSF-PV was weighted as unimportant. The empirical p-value for each optimum sequence according to the different weights was 0.001, 0.0009, and 0.0018 with 10,000 permutations, respectively, indicating statistical significance. A statistical method integrating data on change in gene expression upon multiple antimicrobial exposures is a promising tool for identifying a sequence of antimicrobials that is effective in sustaining reduced CA-MRSA virulence.

Keywords: Staphylococcus aureus; antimicrobials; hollow fiber model; mathematical modeling; virulence.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology*
  • Bacterial Proteins / genetics
  • Clindamycin / pharmacology
  • Community-Acquired Infections / drug therapy*
  • Gene Expression Regulation, Bacterial / drug effects*
  • Linezolid / pharmacology
  • Methicillin-Resistant Staphylococcus aureus / drug effects*
  • Methicillin-Resistant Staphylococcus aureus / genetics
  • Methicillin-Resistant Staphylococcus aureus / growth & development
  • Minocycline / pharmacology
  • Models, Biological*
  • Staphylococcal Infections / drug therapy*
  • Staphylococcus aureus / genetics
  • Trimethoprim, Sulfamethoxazole Drug Combination / pharmacology
  • Vancomycin / pharmacology
  • Virulence / genetics*
  • Virulence Factors / genetics

Substances

  • Anti-Bacterial Agents
  • Bacterial Proteins
  • Virulence Factors
  • Clindamycin
  • Vancomycin
  • Trimethoprim, Sulfamethoxazole Drug Combination
  • Minocycline
  • Linezolid